The Gulf has become the center of gravity for the longevity economy. In roughly two years, the region has produced the field’s first regulatory framework, committed its largest pool of research funding and drawn a growing share of premium-clinic expansion. The Gulf now hosts both the world’s first regulated longevity facility and its largest research funder, two firsts that did not exist anywhere two years ago. The regulatory, financial and physical map of the longevity industry now runs through Abu Dhabi and Riyadh.
This is one of the central industry findings of the 2026 AI Visibility Report. It matters beyond the Gulf, because a shift in where a category is regulated and funded eventually changes where the category is built.
The first rulebook for longevity medicine
In April 2025, Abu Dhabi’s Department of Health established the world’s first evidence-based clinical guidelines for healthy longevity medicine. It was the first time any regulator had defined, in clinical terms, what the practice is and is not. The same authority then licensed the Institute for Healthier Living Abu Dhabi, known as IHLAD, as the first specialized healthy longevity center to operate under a dedicated regulatory framework.
The significance lies in the credibility problem the guidelines address. Longevity medicine has been a category where evidence standards vary widely. A 2025 survey of longevity clinics, widely cited in industry coverage, found that nearly 90 percent provide treatments influenced more by marketing than by scientific evidence. A regulator drawing a clear line between evidence-based practice and everything else is the field’s first structural correction. The framework is also exportable. Once one regulator has shown that licensing longevity-medicine facilities is workable, others have a model to copy.
A licensing regime also changes what a clinic can credibly claim. Before April 2025, any operator could describe itself as a longevity center, and a prospective patient had no external standard against which to test the claim. A regulatory framework creates one. It gives a serious clinic a way to distinguish itself that does not depend on marketing, and it gives a skeptical patient, or a skeptical AI search platform, something concrete to weigh.
The largest pool of money in longevity science
Saudi Arabia’s Hevolution Foundation has committed to deploying up to $1 billion a year toward healthspan research, the largest sovereign-scale funding pool for longevity science in the world. It operates from Riyadh.
Funding at that scale concentrates gravity. Research programs follow the money, scientific talent follows the programs, and drug development follows the talent. The longevity-pharmaceutical pipeline of the next decade will be shaped in part by where its single largest backer sits, and that backer is now in the Gulf.
Hevolution is also a different kind of funder from the ones the category has relied on. Venture capital needs an exit within a fund’s lifetime. Private wealth is patient but rarely deployed at scale. A sovereign foundation spending a billion dollars a year can fund the slow, unglamorous work, the longitudinal studies and the basic geroscience, that the field needs and that commercial money tends to skip. A category funded that way looks different in ten years from one funded only by investors seeking a return.
The luxury map is moving south
The premium-clinic expansion map is following the regulatory and capital shift. Clinique La Prairie, one of the oldest names in luxury longevity, opens an outpost on Saudi Arabia’s Red Sea coast in autumn 2026, the clearest single Gulf move on the map. Lanserhof opens a new location in Marbella in 2027, part of the same broadly southward expansion of the European luxury clinics. Further Gulf and adjacent-market openings are in motion across several established operators.
The pattern is consistent. The brands that define the high end of the category are putting physical capacity closer to the region that is setting its rules and funding its science. Expansion decisions of this size are made years in advance, which means the clinics committing capital to the Gulf now reached that conclusion some time ago.
Why this matters for clinics outside the Gulf
For a clinic in the United States or Europe, the strategic question is no longer whether to engage the Gulf but how. Three consequences follow from the shift.
The Abu Dhabi standards are positioned to become a de facto global reference. A clinic operating under recognized longevity-medicine standards will state that in its content, and AI search increasingly reads compliance with a recognized framework as an authority signal. Standards that began as a local licensing requirement become a citation differentiator everywhere.
Capital concentration accelerates consolidation. Sovereign-scale funding speeds the development of drugs, diagnostics and integrated care models, and it reshapes what every clinic can offer and what it competes against. A clinic planning its next five years against the category as it looked in 2023 is planning against a category that no longer exists.
The Gulf is also becoming a destination market for international longevity patients. That makes it a market AI search will increasingly localize toward, with its own emerging set of cited authorities. Clinics that want a share of Gulf-origin demand will need content that AI search can find when the question is asked from, or about, the region.
The longevity economy spent its first phase centered on California’s diagnostic-driven clinics and the Alpine retreats of Europe. Its next phase has a third pole, and that pole is writing the rules and signing the checks. The clinics that recognize the shift early will be the ones positioned within it.